A troubling disconnect between medical expertise and insurance mandates is putting patients' health at risk. Policies like step therapy and prior authorization are forcing individuals into treatments ...

BIO President & CEO John F. Crowley released the following statement: “A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic ...

Jeff is a registered patent attorney and an intellectual property and innovation policy professional with a unique combination of training and real-world experience. Jeff has done policy work for ...

Barbara Fiacco is a Partner, co-chair of the Intellectual Property Department and co-chair of the Patent, Trade Secrets, and Related Rights Litigation Practice at Foley Hoag LLP. In her practice, ...

Ryan is a nationally recognized patent litigator who represents clients in the pharmaceutical, biotech, consumer products, telecommunications and high-tech sectors in District Courts, the Federal ...

Pamela Torpey is a Principal Counsel in the Global Intellectual Property Department at Sanofi, bringing over 25 years of experience in the biotechnology and pharmaceutical industries. Since joining ...

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities. "Manufacturers should have the choice to effectuate ...

Jessica is an intellectual property litigator with a focus on patent and trade secret litigation. She has represented clients in a variety of technological fields, including AI, data analytics, gaming ...

Kevin E. Noonan is co-Chair of MBHB’s Biotechnology and Pharmaceuticals Practice Group. Dr. Noonan is an experienced patent lawyer, molecular biologist and renowned thought leader in biotechnology and ...

Today, we explore BIO’s recommendations for how CMS can safeguard patient access under Medicare Part D, along with insights on a California Supreme Court case that could affect the complex drug ...

This is the only conference focused specifically on intellectual property in biotechnology, featuring the latest insights from biotech IP experts, as well as networking events designed to promote ...

A collaborative initiative to advance corporate board diversity through partnerships and more.